Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib
Roche and Exelixis detail rare success for Cabometyx-Tecentriq combo in prostate cancer
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
Detailed top-line results from Phase III CONTACT-02 trial demonstrated statistically significant progression-free survival benefit for combination of Cabometyx® and atezolizumab in metastatic...
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 22, 2023-- Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from CABINET, a phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) compared with placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort of patients with advanced pancreatic neuroendocrine tumors (pNET) and a second cohort of patients with advanced extra-pancreatic NET (epNET). The study met the primary objective for each cohort, demonstrating that cabozantinib provided dramatic improvements in median progression-free survival (PFS) for the patients in the pNET and epNET cohorts. The data are being presented today at 8:40 a.m. CET during the Proffered Paper Session – NETs and Endocrine Tumours at the 2023 European Society of Medical Oncology (ESMO) Congress (LBA53) by the Alliance for Clinical Trials in Oncology. CABINET is sponsored by the National Cancer Institute (NCI), part of National Institutes of Health, and is led by the NCI-funded Alliance for Clinical Trials in Oncology and conducted by the NCI-funded National Clinical Trials Network Group.
It's not always a good thing when a drug developer stops a cancer trial. But in a recent case for Exelixis, a Cabometyx trial ended early because of an undeniable efficacy showing.
Exelixis has settled a patent dispute over Teva’s attempt to market a generic version of its blockbuster cancer drug Cabometyx, pushing generic competition into the next decade.
Roche and Exelixis’ combination of Tecentriq and Cabometyx just can't win. After stumbling in liver cancer and lung cancer, the regimen has failed again.
Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer